Ventricular TachycardiaNCT03437408
Late Potentials and Ablation Index in Ventricular Tachycardia Ablation
A study testing Mapping and ablation in people with Ventricular Tachycardia, run by University Hospital Southampton NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
There is an increasing evidence regarding the efficacy of a substrate-based ablation approach to ventricular tachycardia (VT). This approach involves identifying regions of scar and also areas displaying late potentials and fractionated activity. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Ventricular Tachycardia
- What is being tested?
- Mapping and ablation
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 26 Jun 2019to 22 Oct 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Ventricular Tachycardia; scheduled for ablation on clinical grounds; able/willing to consent to procedure/research protocol; no contraindication to clinical ablation; ≥18 years old
Who cannot join
- Unable/unwilling to consent; contraindication to clinical ablation
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Southampton General Hospital
Southampton, Hampshire, SO16 6YD
About this study
Official title: Influence of Ventricular Pacing on Automated Ventricular Substrate Mapping and Relationship Between Ablation Index and Impedance Drop in the Human Ventricle
There is an increasing evidence regarding the efficacy of a substrate-based ablation approach to ventricular tachycardia (VT). This approach involves identifying regions of scar and also areas displaying late potentials and fractionated activity. Automated mapping systems are now available which may be able to generate high density maps displaying regions containing both late potentials and ventricular scar. Such an automated approach has not been validated. Furthermore, most patients presenting for VT ablation have pacing devices in situ. It is not known how the pacing modality affect the substrate maps generated for these procedures. Once an area felt to be important to ablate has been identified, the next key step is to perform effective ablation. An algorithm has now been made available (Ablation index - Biosense Webster Inc.,) which in preclinical studies is an effective predictor of radiofrequency lesion depth. This algorithm has been studied extensively in the atrium but not in the ventricle. This study would also seek to collect ablation index data during ablation to assess the algorithm during ventricular ablation.
Read the detailed description
The study would propose to use the Carto3 mapping system with the Confidense automated tagging module (Biosense Webster Inc.,) and a high density mapping catheter to generate substrate maps of the ventricle, with maps generated with varying pacing modes. A SmartTouch catheter (Biosense Webster Inc.,) would then be used for ablation with data collected during each ablation.
The study hypotheses are:
- High density automated mapping systems can be used to generate accurate ventricular substrate maps.
- There will be a significant change in the late potential maps based on the presence and type of ventricular pacing.
- The relationship between impedance drop and ablation index during ablation will be stronger than FTI and will allow formulation of an upper limit for clinical ventricular ablation.
- The relationship between FTI and AI with impedance drop will be stronger than with electrogram attenuation.
Protocol:
15 patients, listed on clinical grounds for a left ventricular VT ablation in the context of structural heart disease (including redo ablation) would be recruited for the trial. All patients would need to have a pacing device in situ and have underlying sensed ventricular rhythm (with or without atrial pacing), or in the absence of a sensed ventricular rhythm, a biventricular pacing device. As part of their clinical work-up for the procedure, patients will have cardiac MRI scans wherever possible.
All procedures would be undertaken with Carto3, using a PentaRay catheter for mapping in concert with the Confidense module, and a SmartTouch or SmartTouch SF catheter for ablation (Biosense Webster).
Procedures would be conducted under moderate ('conscious') sedation or general anaesthetic.
Mapping Phase Mapping would be performed antegrade, retrograde or a combination of both. The first map taken would be without ventricular pacing using the PentaRay catheter and Confidense. Confidense maps would be displayed showing bipolar voltage and late potentials in Carto3. The aim would be for maximal coverage of the ventricle. A remap would then be undertaken with pacing from the patient's right ventricular pacing lead. In patients with an additional left ventricular lead, maps would also be made with left ventricular only and biventricular pacing. In those patient without underlying ventricular sensed rhythm, maps would be taken with right ventricular only, left ventricular only and biventricular pacing.
The automatically collected maps would then be validated. The PentaRay would be moved over to 2 areas where there is agreement between the maps over the presence of late potentials and, while the PentaRay was kept in the same place, manual points would be taken with one pacing mode and then with the pacing mode changed. This would also be repeated for 2 areas where there is disagreement over the presence of late potentials. This process would also be repeated for areas identified as showing scar. All points would be taken with respiratory gating. Off line, the areas identified as showing abnormal signal - either scar or late potentials - would be manually checked to ensure the system has correctly identified them.
Ablation Phase Ablation would be undertaken using a Smart Touch Surround Flow Catheter (Biosense Webster). Ablation power would be restricted to 40-50W based on the operator's choice. Steerable sheath usage would be encouraged but not mandatory. Each radiofrequency application would be delivered with the catheter stable prior to the ablation. A mapping point would be taken with the catheter stable, and then a static ablation would be delivered and an ablation point manually taken. Following cessation of ablation, a further mapping point would be taken. All points would be respiratory gated. Ablations would be non-overlapping. If there was displacement of the catheter during the ablation, this ablation would be removed from the impedance analysis.
Quantitative comparisons Mapping Study The percentage of the maps showing scar and late potentials would be quantitatively analysed by exporting the data from Carto3. As comparisons would be made between pacing modes, each patient would act as their own control. Based on prior work, bipolar scar would be defined as <0.5mv for dense scar and 0.5-1.5mV for low voltage areas12, while unipolar scar would be <5mV. The characteristic of the late potentials - specifically how late they were compared to the QRS and their size would be compared quantitatively for electrograms taken manually at the same location with the PentaRay. Quantitative analyses of the data exported from Carto 3 would be conducted using novel algorithms programmed in Matlab (Mathworks, Natick, MA, USA).
Ablation Study The Carto3 data export would be utilized to obtain the impedance, contact force, temperature and location data and electrogram data (pre- and post-ablation) for each ablation. These data would then be analysed using custom Matlab scripts to undertake an incremental AI and FTI based analysis of the impedance drop during ablation. The curves would then be analyzed with the target of quantitatively describing the relationships with impedance drop and if possible providing the plateau points in the curve to generate an upper limit for ablation.
Value of Results This study would assess automated electrogram collection as a valid methodology for rapidly generating ventricular substrate maps. This will help to shorten procedure times for VT ablation by guiding the physician to the areas of interest more rapidly. At present, it is unknown how the pacing mode affects substrate maps in the ventricle and consequently the mode in which to leave pacing. The study will help to guide us to maximise the appropriate identification of the VT substrate by picking the correct pacing mode for the procedure.
The study would validate the use of ablation index for clinical ventricular ablation as well as aiming to provide guidance as to how to use this for maximal safety and efficacy.
- Conditions
- Ventricular Tachycardia
- Being tested
- Mapping and ablation
- Keywords
- Ventricular Tachycardia, Catheter Ablation, Late Potential, Ablation Index, Pacing
- Medical subject headings
- Tachycardia, Ventricular
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mapping and ablationDevice
High density substrate map. Data collection during ablation
| Study group | Role | What they receive |
|---|---|---|
| Mapping and ablation | Experimental | Automated Substrate maps with different pacing modes. Validation of collected substrate. Data collection during ablation Receives: Device: Mapping and ablation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Areas with ventricular tachycardia substrate
Quantification of late potential area and scar area with comparison between pacing modalities
Measured: Through study completion, an average of 1 year
Secondary outcomes (3)
Relationship between ablation index and impedance drop
Quantification of the relationship between ablation index and impedance drop during ablation.
Measured: Through study completion, an average of 1 year
Relationship between Force Time Integral and impedance drop
Quantification of the relationship between Force Time Integral and impedance drop during ablation.
Measured: Through study completion, an average of 1 year
Relationship between electrogram attenuation and impedance drop
Quantification of the relationship between electrogram attenuation and impedance drop during ablation.
Measured: Through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Feb 2018
- Study start26 Jun 2019
- Primary completion22 Oct 2020
- Study completion22 Oct 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Ventricular TachycardiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Ventricular Substrate maps in patients undergoing ablation for VT - maps collected with automated tagging in different pacing modalities. Validation of collected substrate. Collection of impedance and ablation index data during ablation
- Masking
- None (open label)
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital Southampton NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Collaborators
- Biosense Webster, Inc.
- Responsible party
- Sponsor
- Investigators
- Waqas Ullah, PhD, Principal investigator, University Hospital Southampton NHS Foundation Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03437408
- Sponsor's protocol ID
- RHM CAR0538
- Status last verified
- Sep 2021
- First submitted
- 2 Feb 2018
- Last updated
- 29 Sep 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No plans to share IPD
Publications
Bates AP, Paisey J, Yue A, Banks P, Roberts PR, Ullah W. Radiofrequency Ablation of the Diseased Human Left Ventricle: Biophysical and Electrogram-Based Analysis. JACC Clin Electrophysiol. 2023 Mar;9(3):330-340. doi: 10.1016/j.jacep.2022.10.001. Epub 2022 Oct 10.
PubMed 36371330
Study at a glance
From the registry record, last updated by the sponsor on 29 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Influence of Ventricular Pacing on Automated Ventricular Substrate Mapping and Relationship Between Ablation Index and Impedance Drop in the Human Ventricle
- ClinicalTrials.gov ID
- NCT03437408
- Acronym / sponsor ID
- RHM CAR0538
- Conditions
- Ventricular Tachycardia
- Keywords
- Ventricular Tachycardia, Catheter Ablation, Late Potential, Ablation Index, Pacing
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- University Hospital Southampton NHS Foundation TrustUniversity, hospital or other
- Collaborators
- Biosense Webster, Inc.
- Study start
- 26 Jun 2019 (actual)
- Primary completion
- 22 Oct 2020 (actual)
- Study completion
- 22 Oct 2020 (actual)
- First posted
- 19 Feb 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
There is an increasing evidence regarding the efficacy of a substrate-based ablation approach to ventricular tachycardia (VT). This approach involves identifying regions of scar and also areas displaying late potentials and fractionated activity. Automated mapping systems are now available which may be able to generate high density maps displaying regions containing both late potentials and ventricular scar. Such an automated approach has not been validated. Furthermore, most patients presenting for VT ablation have pacing devices in situ. It is not known how the pacing modality affect the substrate maps generated for these procedures. Once an area felt to be important to ablate has been identified, the next key step is to perform effective ablation. An algorithm has now been made available (Ablation index - Biosense Webster Inc.,) which in preclinical studies is an effective predictor of radiofrequency lesion depth. This algorithm has been studied extensively in the atrium but not in the ventricle. This study would also seek to collect ablation index data during ablation to assess the algorithm during ventricular ablation.
Detailed description
The study would propose to use the Carto3 mapping system with the Confidense automated tagging module (Biosense Webster Inc.,) and a high density mapping catheter to generate substrate maps of the ventricle, with maps generated with varying pacing modes. A SmartTouch catheter (Biosense Webster Inc.,) would then be used for ablation with data collected during each ablation.
The study hypotheses are:
- High density automated mapping systems can be used to generate accurate ventricular substrate maps.
- There will be a significant change in the late potential maps based on the presence and type of ventricular pacing.
- The relationship between impedance drop and ablation index during ablation will be stronger than FTI and will allow formulation of an upper limit for clinical ventricular ablation.
- The relationship between FTI and AI with impedance drop will be stronger than with electrogram attenuation.
Protocol:
15 patients, listed on clinical grounds for a left ventricular VT ablation in the context of structural heart disease (including redo ablation) would be recruited for the trial. All patients would need to have a pacing device in situ and have underlying sensed ventricular rhythm (with or without atrial pacing), or in the absence of a sensed ventricular rhythm, a biventricular pacing device. As part of their clinical work-up for the procedure, patients will have cardiac MRI scans wherever possible.
All procedures would be undertaken with Carto3, using a PentaRay catheter for mapping in concert with the Confidense module, and a SmartTouch or SmartTouch SF catheter for ablation (Biosense Webster).
Procedures would be conducted under moderate ('conscious') sedation or general anaesthetic.
Mapping Phase Mapping would be performed antegrade, retrograde or a combination of both. The first map taken would be without ventricular pacing using the PentaRay catheter and Confidense. Confidense maps would be displayed showing bipolar voltage and late potentials in Carto3. The aim would be for maximal coverage of the ventricle. A remap would then be undertaken with pacing from the patient's right ventricular pacing lead. In patients with an additional left ventricular lead, maps would also be made with left ventricular only and biventricular pacing. In those patient without underlying ventricular sensed rhythm, maps would be taken with right ventricular only, left ventricular only and biventricular pacing.
The automatically collected maps would then be validated. The PentaRay would be moved over to 2 areas where there is agreement between the maps over the presence of late potentials and, while the PentaRay was kept in the same place, manual points would be taken with one pacing mode and then with the pacing mode changed. This would also be repeated for 2 areas where there is disagreement over the presence of late potentials. This process would also be repeated for areas identified as showing scar. All points would be taken with respiratory gating. Off line, the areas identified as showing abnormal signal - either scar or late potentials - would be manually checked to ensure the system has correctly identified them.
Ablation Phase Ablation would be undertaken using a Smart Touch Surround Flow Catheter (Biosense Webster). Ablation power would be restricted to 40-50W based on the operator's choice. Steerable sheath usage would be encouraged but not mandatory. Each radiofrequency application would be delivered with the catheter stable prior to the ablation. A mapping point would be taken with the catheter stable, and then a static ablation would be delivered and an ablation point manually taken. Following cessation of ablation, a further mapping point would be taken. All points would be respiratory gated. Ablations would be non-overlapping. If there was displacement of the catheter during the ablation, this ablation would be removed from the impedance analysis.
Quantitative comparisons Mapping Study The percentage of the maps showing scar and late potentials would be quantitatively analysed by exporting the data from Carto3. As comparisons would be made between pacing modes, each patient would act as their own control. Based on prior work, bipolar scar would be defined as <0.5mv for dense scar and 0.5-1.5mV for low voltage areas12, while unipolar scar would be <5mV. The characteristic of the late potentials - specifically how late they were compared to the QRS and their size would be compared quantitatively for electrograms taken manually at the same location with the PentaRay. Quantitative analyses of the data exported from Carto 3 would be conducted using novel algorithms programmed in Matlab (Mathworks, Natick, MA, USA).
Ablation Study The Carto3 data export would be utilized to obtain the impedance, contact force, temperature and location data and electrogram data (pre- and post-ablation) for each ablation. These data would then be analysed using custom Matlab scripts to undertake an incremental AI and FTI based analysis of the impedance drop during ablation. The curves would then be analyzed with the target of quantitatively describing the relationships with impedance drop and if possible providing the plateau points in the curve to generate an upper limit for ablation.
Value of Results This study would assess automated electrogram collection as a valid methodology for rapidly generating ventricular substrate maps. This will help to shorten procedure times for VT ablation by guiding the physician to the areas of interest more rapidly. At present, it is unknown how the pacing mode affects substrate maps in the ventricle and consequently the mode in which to leave pacing. The study will help to guide us to maximise the appropriate identification of the VT substrate by picking the correct pacing mode for the procedure.
The study would validate the use of ablation index for clinical ventricular ablation as well as aiming to provide guidance as to how to use this for maximal safety and efficacy.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Ventricular Substrate maps in patients undergoing ablation for VT - maps collected with automated tagging in different pacing modalities. Validation of collected substrate. Collection of impedance and ablation index data during ablation
| Arm | Type | Receives |
|---|---|---|
| Mapping and ablation | Experimental | Device: Mapping and ablationAutomated Substrate maps with different pacing modes. Validation of collected substrate. Data collection during ablation |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Ventricular Tachycardia; scheduled for ablation on clinical grounds; able/willing to consent to procedure/research protocol; no contraindication to clinical ablation; ≥18 years old
Key exclusion criteria (1 listed)
- Unable/unwilling to consent; contraindication to clinical ablation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mapping and ablationHigh density substrate map. Data collection during ablation | Device | Mapping and ablation |
Primary outcome
Areas with ventricular tachycardia substrate
Time frame: Through study completion, an average of 1 year
Quantification of late potential area and scar area with comparison between pacing modalities
3 secondary outcomes
Relationship between ablation index and impedance drop
Time frame: Through study completion, an average of 1 year
Relationship between Force Time Integral and impedance drop
Time frame: Through study completion, an average of 1 year
Relationship between electrogram attenuation and impedance drop
Time frame: Through study completion, an average of 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Sep 2021.
- Derived from this study: PubMed 36371330Bates AP, Paisey J, Yue A, Banks P, Roberts PR, Ullah W. Radiofrequency Ablation of the Diseased Human Left Ventricle: Biophysical and Electrogram-Based Analysis. JACC Clin Electrophysiol. 2023 Mar;9(3):330-340. doi: 10.1016/j.jacep.2022.10.001. Epub 2022 Oct 10.
- Individual participant dataSharing planned: No. No plans to share IPD
Related trials for Ventricular Tachycardia
Enrolling by invitation
VINTAGE (Ventricular Intramyocardial Navigation for Tachycardia Ablation Guided by Electrograms) Using Commercial Off-The-Shelf (COTS) Catheters
Ventricular Arrhythmia
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Recruiting
A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter
Scar-related Atrial Tachycardia, Persistent Atrial Fibrillation
RecruitingObservational study
Genetic Markers of Cardiovascular Disease in Epilepsy
Epilepsy, Seizures
Recruiting
Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)
Tachycardia, Ventricular
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Waqas Ullah, PhD principal investigator
University Hospital Southampton NHS Foundation Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mapping and ablation in people with Ventricular Tachycardia, run by University Hospital Southampton NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Areas with ventricular tachycardia substrate (time frame: Through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03437408, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2021.